Size : | Price | Quantity | |
---|---|---|---|
10 mg | $44.00 | ||
50 mg | $130.00 |
Vildagliptin (274901-16-5) is a potent inhibitor of dipeptidyl peptidase IV (DPP IV), an enzyme that cleaves glucagon-like peptide 1 (GLP-1).1 Delaying the degradation of GLP-1 extends the action of insulin and suppressing the release of glucagon which results in reduction in elevated blood glucose levels (hyperglycemia).2 Clinically useful antidiabetic agent. Ameliorates cognitive deficits in streptozotocin-induced Alzheimer’s disease model.3 Displays protective effects on β-cells by inhibition of ER stress in a mouse model.4
References/Citations:
1) Balas et al. (2007), The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients; J. Clin. Endocrinol. Metab., 92 1249
2) Ahren et al. (2004), Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes; J. Clin. Endocrinol. Metab., 89 2078
3) Kosaraju et al. (2013), Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer’s disease; J. Pharm. Pharmacol., 65 1773
4) Shimizu et al. (2012), DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice; J. Mol. Endocrinol., 49 125
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Vildagliptin (274901-16-5) is a potent inhibitor of dipeptidyl peptidase IV (DPP IV), an enzyme that cleaves glucagon-like peptide 1 (GLP-1).1 Delaying the degradation of GLP-1 extends the action of insulin and suppressing the release of glucagon which results in reduction in elevated blood glucose levels (hyperglycemia).2 Clinically useful antidiabetic agent. Ameliorates cognitive deficits in streptozotocin-induced Alzheimer’s disease model.3 Displays protective effects on β-cells by inhibition of ER stress in a mouse model.4
References/Citations:
1) Balas et al. (2007), The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients; J. Clin. Endocrinol. Metab., 92 1249
2) Ahren et al. (2004), Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes; J. Clin. Endocrinol. Metab., 89 2078
3) Kosaraju et al. (2013), Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer’s disease; J. Pharm. Pharmacol., 65 1773
4) Shimizu et al. (2012), DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice; J. Mol. Endocrinol., 49 125
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.